Application | Comment | Organism |
---|---|---|
drug development | RNase H activity is an attractive target for a new class of antiviral drugs | Human immunodeficiency virus 1 |
Cloned (Comment) | Organism |
---|---|
cloning a His-tagged p66 or p51 HIV-1 RT DNA fragment into the pQE-9 vector and expression in Escherichia coli strain BL21(DE3)pLys | Human immunodeficiency virus 1 |
Protein Variants | Comment | Organism |
---|---|---|
C280S | site-directed mutagenesis | Human immunodeficiency virus 1 |
F160S | site-directed mutagenesis | Human immunodeficiency virus 1 |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
2-(2,3-dihydro-1H-inden-1-ylamino)-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-(2,3-dihydro-1H-inden-2-ylamino)-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-(tert-butylamino)-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-amino-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-oxo-2-(1,2,3,4-tetrahydronaphthalen-1-ylamino)ethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-oxo-2-(propan-2-yloxy)ethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-oxo-2-(tetrahydrofuran-2-ylamino)ethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-oxo-2-[(2-phenylpropan-2-yl)amino]ethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[(2-methyl-1-phenylpropan-2-yl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[(2-methylbutan-2-yl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[(4-hydroxybenzyl)(tetrahydrofuran-2-ylmethyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[benzyl(tetrahydrofuran-2-ylmethyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[tert-butyl(2-phenylethyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[tert-butyl(3-nitrobenzyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[tert-butyl(3-oxo-3-phenylpropyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[tert-butyl(3-phenylpropyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[tert-butyl(4-fluorobenzyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[tert-butyl(4-methoxybenzyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[tert-butyl(4-nitrobenzyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[tert-butyl(pentafluorobenzyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[tert-butyl(phenyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[tert-butyl[2-(trifluoromethyl)benzyl]amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[tert-butyl[3-(trifluoromethyl)benzyl]amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[tert-butyl[4-(trifluoromethyl)benzyl]amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[[2-(acetyloxy)benzyl](tert-butyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[[4-(acetyloxy)benzyl](tert-butyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
2-[[4-(benzyloxy)benzyl](tert-butyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
3,3-dimethyl-2-oxobutyl 5-nitrofuran-2-carboxylate | - |
Human immunodeficiency virus 1 | |
additional information | design, synthesis, and screening of derivatives of 5-nitro-furan-2-carboxylic acid as inhibitors of the RNAse H activity of HIV-1 reverse transcriptase, overview. Modulation of the 5-nitro-furan-2-carboxylic moiety results in a drastic decrease in inhibitory potency. Binding mode of active derivatives, in which three oxygen atoms aligned in a straight form at the nitro-furan moiety are coordinated to two divalent metal ions located at RNase H reaction site. The nitro-furan-carboxylic moiety is one of the critical scaffolds for RNase H inhibition. Cytotoxicity of the synthesized compounds, overview | Human immunodeficiency virus 1 |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
additional information | Human immunodeficiency virus 1 | HIV-1 reverse transcriptase has two enzymatic functions, DNA polymerase and RNase H activities | ? | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Human immunodeficiency virus 1 | - |
HIV-1 | - |
Purification (Comment) | Organism |
---|---|
recombinant His-tagged p66 or p51 HIV-1 RT DNA fragment from Escherichia coli strain BL21(DE3)pLys by nickel affinity chromatography, expression of a heterodimer of wild-type or F160S and C280S mutant p66 and p51 using plasmid vector RT69A in Escherichia coli strain Rosetta | Human immunodeficiency virus 1 |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
additional information | HIV-1 reverse transcriptase has two enzymatic functions, DNA polymerase and RNase H activities | Human immunodeficiency virus 1 | ? | - |
? |
Synonyms | Comment | Organism |
---|---|---|
RNase H | - |
Human immunodeficiency virus 1 |
Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|
37 | - |
assay at | Human immunodeficiency virus 1 |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
7.5 | - |
assay at | Human immunodeficiency virus 1 |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.0009 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[tert-butyl(phenyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.0042 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-oxo-2-(tetrahydrofuran-2-ylamino)ethyl 5-nitrofuran-2-carboxylate | |
0.0043 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[(2-methyl-1-phenylpropan-2-yl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.0043 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-oxo-2-(1,2,3,4-tetrahydronaphthalen-1-ylamino)ethyl 5-nitrofuran-2-carboxylate | |
0.005 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[(4-hydroxybenzyl)(tetrahydrofuran-2-ylmethyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.0055 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-(2,3-dihydro-1H-inden-2-ylamino)-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.0058 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[(2-methylbutan-2-yl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.0061 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-(2,3-dihydro-1H-inden-1-ylamino)-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.0068 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[tert-butyl(pentafluorobenzyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.0069 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[tert-butyl(4-nitrobenzyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.0071 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-amino-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.0075 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[tert-butyl(4-methoxybenzyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.0077 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[benzyl(tetrahydrofuran-2-ylmethyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.008 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[tert-butyl[4-(trifluoromethyl)benzyl]amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.0082 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-oxo-2-[(2-phenylpropan-2-yl)amino]ethyl 5-nitrofuran-2-carboxylate | |
0.0085 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[tert-butyl(4-fluorobenzyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.0085 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[tert-butyl[3-(trifluoromethyl)benzyl]amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.0087 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[[4-(acetyloxy)benzyl](tert-butyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.009 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[tert-butyl[2-(trifluoromethyl)benzyl]amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.0098 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[tert-butyl(3-nitrobenzyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.0128 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[[2-(acetyloxy)benzyl](tert-butyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.0132 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-oxo-2-(propan-2-yloxy)ethyl 5-nitrofuran-2-carboxylate | |
0.0142 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[tert-butyl(2-phenylethyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.018 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-(tert-butylamino)-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.0219 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 3,3-dimethyl-2-oxobutyl 5-nitrofuran-2-carboxylate | |
0.05 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[tert-butyl(3-phenylpropyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.05 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[tert-butyl(3-oxo-3-phenylpropyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate | |
0.05 | - |
pH 7.5, 37°C | Human immunodeficiency virus 1 | 2-[[4-(benzyloxy)benzyl](tert-butyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate |